On behalf of the Board of Directors,
I extend a warm welcome to all of you to the 23rd Annual General
Meeting of our company.
I am delighted to say that throughout the year our company continued to
evolve and expand, still remaining focused on its core strategy of
becoming a leading Manufacturer & Exporter of Pharmaceutical products
across the globe. While we continue to operate in the same industry,
the services we provide, as a result of our merger and acquisition
activity, have expanded considerably.
To realise better results from a performance-oriented approach, our
Company has also increased performance-linked incentives and introduced
mentoring programmes for our employees. We are continuously expanding
our sales and marketing reach, My primary aim is to reignite growth and
to rebuild the high-performance culture of the Company, as well as a
value system all stakeholders can be proud of.
On the production front, our Thane factory have been augmented and
restructured. As we regain momentum, we will continue to deliver value
to our customers and stimulating, challenging work to our people, while
we create a better working environment, in which our existing and new
employees can thrive.
I strongly believe that we enjoy a robust foundation that will support
growth across all our lines of businesses. We have demonstrated our
capabilities in different segments and markets across the globe.
I intend to continue to leverage this solid platform to achieve our
aspirations and deliver value to our stakeholders. As we step into a
new phase of vitality, we continue to rely on this support and
Mukund P. Mehta